Дизайн, синтез и биологические свойства ингибиторов ВСR-ABL тирозинкиназы, применяемых для лечения хронического миелолейкоза
Эффективность лечения хронического миелолейкоза существенно повысилась после введения в клиническую практику иматиниба - селективного ингибитора BCR-ABL тирозинкиназы. Описаны история разработки иматиниба, методы его синтеза и направления дальнейшей оптимизации структуры.
1. Fialkow, P. J. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage / P. J. Fialkow, R. J. Jacobson, T. Papayannopoulou // Am J Med. - 1977. - Vol. 63, № 1. -P. 125-130.
2. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death / A. McGahon [et al.]// Blood. - 1994. - Vol. 83, N 12. - P. 1179-1187.
3. Williams hematology, 6th ed. / E. Beutler [et al.]. - New York: McGraw-Hill, 2001.
4. Nowell, P. A minute chromosome in human chronic granulocytic leukemia / P. Nowell, D. A. Hungerford // Science. -1960. - Vol. 142. - P. 1497.
5. Nowell, P. C. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia / P. C. Nowell, D. A. Hungerford // J. Natl. Cancer Inst. - 1961. - Nov. Vol. 27. - P. 1013-1035.
6. Rowley, J. D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining / J. D. Rowley // Nature. - 1973. - Vol. 243, N 5405. - P. 290-293.
7. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products / T. G. Lugo [et al.] // Science. -1990. - Vol. 247 - P. 1079-1082.
8. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics / R. Kurzrock [et al.] // Ann Intern Med. - 2003. - Vol. 138, N 10. - P. 819-830.
9. Tumors of Haematopoietic and Lymphoid Tissues / J. W. Vardiman [et al.] - Lyon: IARCPress, 2009. - P. 15-59.
10. Savage, D. G. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period / D. G. Savage, R. M. Szydlo, J. M. Goldman // Br. J. Haematol. - 1997. - Vol. 96. - P. 111-116.
11. Kantarjian, H. M. Chronic myelogenous leukemia: a concise update / H. M. Kantarjian [et al.] // Blood. - 1993. -Vol. 82. - P. 691-703.
12. Fialkow, P. J. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage / P. J. Fialkow, R. J. Jacobson, T. Papayannopoulou // Am. J. Med. - 1977. - Vol. 63, N 1. - P. 125-130.
13. Kantarjian, H. M. Definition of the accelerated phase of chronic myelogenous leukemia (letter) / H. M. Kantarjian, M. Talpaz // J. Clin. Oncol. - 1988. - Vol. 6. - P. - 180-182.
14. Kantarjian, H. M. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients / H. M. Kantarjian [et al.] // Am. J. Med. - 1987. - Vol. 83. - P. 445-454.
15. Goldman, J. M. Chronic myeloid leukemia: current treatment options / J. M. Goldman, B. J. Druker // Blood. - 2001. -Vol. 98. - P. 2039-2042.
16. Cortes, J. E. Chronic myelogenous leukemia: a review / J. E. Cortes, M. Talpaz, H. Kantarjian// Am. J. Med. - 1996. -Vol. 100, N 5. - P. 555-570.
17. Clinical investigation of human alpha interferon in chronic myelogenous leukemia /M. Talpaz[et al.] // Blood. - 1987. -Vol. 69, N 5. - P. 1280-1298.
18. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials / Chronic Myeloid Leukemia Trialists' Collaborative Group // J. Natl. Cancer Inst. - 1997. - Vol. 89, N 21. - P. 1616-1620.
19. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service / H. M. Kantarjian [et al.] // Ann. Intern. Med. - 1995. - Vol. 122. - P. 254-261.
20. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine // H. M. Kantarjian [et al.] // J. Clin. Oncol. - 1999. - Vol. 17. - P. 284-292.
21. Talpaz, M. The interferon-alpha revival in CML / M. Talpaz, J. Mercer, R. Hehlmann// Ann. Hematol. - 2015. - Vol. 94, Suppl 2. - P. 195-207.
22. Approval summary for imatinibmesylate capsules in the treatment of chronic myelogenous leukemia / M. H. Cohen [et al.] // Clin. Cancer Res. - 2002. - Vol. 8, N 5. - P. 935-942.
23. Approval summary: imatinibmesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase / J. R. Johnson [et al.] //Clin. Cancer Res. - 2003. - Vol. 9, N 6. - P. 1972-1979.
24. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials / L. Roy [et al.] // Blood. - 2006. - Vol. 108, N 5. - P. 1478-1484.
25. International randomized study of interferon vs STI571 (IRIS) 8-year follow uP. sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib / M. Deininger [et al.] // Blood. - 2009. - Vol. 114. - P. 1126.
26. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience / H. Kantarjian [et al.] // Blood. - 2012. - Vol. 119, N 9. - P. 1981-1987.
27. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. M. Talpaz [et al.] // Blood. - 2002. - Vol. 99. - P. 1928-1937.
28. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study / C. L. Sawyers [et al.] // Blood. - 2002. - Vol. 99. - P. 3530-3539.
29. Evolution of therapies for chronic myelogenous leukemia / F. P. Santos [et al.] // Cancer J. - 2011. - Vol. 17. N 6 - P. 465-476.
30. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia / S. G. O'Brien [et al.] // N. Engl. J. Med. - 2003. - Vol. 348. - P. 994-1004.
31. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia / B. J. Druker [et al.] // N. Engl. J. Med. - 2006. - Vol. 355. - P. 2408-2417.
32. Jabbour, E. Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm / E. Jabbour, H. Kantarjian, J. Cortes //Clin. Lymphoma Myeloma. Leuk. - 2015. -Vol. 15, N 6. - P. 323-334.
33. A review of the European LeukemiaNet recommendations for the management of CML / M. Baccarani [et al.] // Ann. Hematol. - 2015. - Vol. 94, Suppl 2. - P. 141-147.
34. Chronic myelogenous leukemia: a review and update of therapeutic strategies / G. Garcia-Manero [et al.] // Cancer. -2003. - Vol. 98, N 3. - P. 437-457.
35. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia / R. Hehlmann [et al.] // Blood. - 2007. - Vol. 109, N 11. - P. 4686-4692.
36. Leitner, A. A. Current treatment concepts of CML. / A. A. Leitner, A. Hochhaus, M. C. Muller // Curr. Cancer Drug. Targets. - 2011. - Vol. 11, N 1. - P. 31-43.
37. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphos-tins / M. Anafi [et al.] // J. Biol. Chem. - 1992. - Vol. 267, N 7. - P. 4518-4523.
38. Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycinA / Y. Uehara [et al.] // Virology. -1988. - Vol. 164, N 1. - P. 294-298.
39. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC) / J. Zimmermann [et al.] // Arch. Pharm. - 1996. - Vol. 329, N 7. - P. 371-376.
40. Phenylamino-pyrimidine (PAP)-derivatives: a new class of potent and highly selective PDGF-receptor autophos-phorylation inhibitors / J. Zimmermann [et al.] // Bioorg. MedChem. Lett. - 1996. - Vol. 6. - P. 1221-1226.
41. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug / R. Capdeville [et al.] // Nat. Rev. Drug Discov. - 2002. - Vol. 1, N 7. - P. 493-502.
42. Deininger, M. The development of imatinib as a therapeutic agent for chronic myeloid leukemia / M. Deininger, E. Buchdunger, B. J. Druker // Blood. - 2005. - Vol. 105, N 7 - P. 2640-2653.
43. Pyrimidine derivatives and processes for the preparation thereof: US Pat. 5521184 / J. Zimmermann; датапубл.: 28.05.1996.
44. N-phenyl-2-pyrimidine-amine derivatives: world pat. WO2003066613 / O. Loiseleur [et al.]; дата публ.: 14.08.2003.
45. The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib / B. J. Deadman [et al.] // Org. Biomol. Chem. - 2013. - Vol. 11, N 11. - P. 1766-800.
46. A practical synthesis of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid-the key precursor toward imatinib / E. V. Koroleva [et al.] // Tetrahedron Letters. - 2012. - Vol. 53. - P. 5056-5058.
47. Способ получения метансульфоната 4-[(4-метил-1-пиперазинил)-метил]-N-[4-метил-3-{[4-(3-пиридил)-2-пиримидинил]-амино}фенил]бензамида: пат. 17047 Респ. Беларусь / В. Е. Агабеков [и др.]; дата публ.: 30.04.2013.
48. Способ получения метилового эфира и дигидрохлорида 4-[(4-метилпиперазин-1-ил)метил]-бензойной кислоты: пат. 17842 Респ. Беларусь / Е. В. Королева [и др.]; дата публ.: 30.12.2013.
49. Managementofimatinib-resistantpatientswithchronicmyeloidleukemia / P. K. Bhamidipati [etal.] //Ther. Adv. Hematol. - 2013. - Vol. 4, N 2. - P. 103-117.
50. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib / T. Ernst [et al.] // Haematologica. - 2008. - Vol. 93, N 2. - P. 186-192.
51. Eck, M. J. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl / M. J. Eck, P. W. Manley // Curr. Opin. Cell. Biol. - 2009. - Vol. 21, N 2. - P. 288-295.
52. Lee, F. Overcoming kinase resistance in chronic myeloid leukemia / F. Lee, A. Fandi, M. Voi // Int. J. Biochem. Cell Biol. - 2008. - Vol. 40, N 3. - P. 334-343.
53. Ravandi, F. Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors / F. Ravandi //Clin. Lymphoma Myeloma Leuk. - 2011. - Vol. 11, N 2. - P. 198-203.
54. Valent, P. Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches / P. Valent // Biologics. - 2007. - Vol. 1, N 4. - P. 433-448.
55. FDA approval for nllotlnlb [Электронныйресурс] /US National Institutes of Health, National Cancer Institute. - Режим доступа: httP.//www.cancer.gov/about-cancer/treatment/drugs/fda-nilotinib. - Дата доступа: 18.03.2015.
56. Deremer, D. L. Nilotinib: a second-cgeneration tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia / D. L. Deremer, C. Ustun, K. Natarajan // Clin. Ther. - 2008. - Vol. 30, N 11. - P. 1956-1975.
57. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl / E. Weisberg [et al.] // Cancer Cell. -2005. - Vol. 7, N 2. - P. 129-141.
58. AMN107: tightening the grip of imatinib / T. O'hare [et al.] // Cancer Cell. - 2005. - Vol. 7, N 2. - P. 117-119.
59. Jabbour, E. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review / E. Jabbour, J. Cortes, H. Kantarjian // Core Evid. - 2009. - Vol. 4. - P. 207-213.
60. Manley, P. W. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia / P. W. Manley, S. W. Cowan- Jacob, J. Mestan // Biochim. Biophys. Acta. - 2005. -Vol. 1754, N 1-2. - P. 3-13.
61. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. S. Redaelli [et al.] // J. Clin. Oncol. - 2009. - Vol. 27, N 3. - P. 469-471.
62. Moslehi, J. J. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J. J. Moslehi, M. Deininger // J. Clin. Oncol. - 2015.
63. Miller, G. D. Resistant mutations in CML and Ph(+)ALL - role of ponatinib / G. D. Miller, B. J. Bruno, C. S. Lim // Biologics. - 2014. - Vol. 8. - P. 243-254.
64. Comprehensive analysis of the in vitro potency of ponatinib, and all other approved BCR-ABL tyrosine kinase inhibitors (TKIs), against a panel of single and compound BCR-ABL mutants / M. G. Joseph [et al.] // Blood. - 2013. - Vol. 122, N 21. - P. 3992-3992.
65. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3(trifluo-romethyl) phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant / W. S. Huang [et al.] // J. Med. Chem. - 2010. - Vol. 53, N 12. - P. 4701-4719.
66. European approval of Ponatinib for leukemia. [Электронный ресурс] / Режим доступа: httр.//news.medlive.cn/all/info-progress/show-50240_112. html - Дата доступа: 18.03.2015.
67. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history / E. Jabbour // Leukemia. - 2010. - Vol. 24, N 1. - P. 6-12.
68. Carneiro, B. A. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events / B. A. Carneiro, J. B. Kaplan, F. J. Giles // Expert Rev. Hematol. - 2015. - Vol. 8, N 4. - P. 457-479.
69. FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing. [Электронный ресур^ United States Food and Drug Administration. - Режим доступа: httр.//www.fda.gov/Drugs/DrugSafety/ucm379554.htm. - Дата доступа: 15.05.2015.
70. -(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation / W. S. Huang [et al.] // J. Med. Chem. - 2009. - Vol. 52, N 15. - P. 4743-4756.
71. Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors / L. Hu [et al.] // Bioorg. Med. Chem. - 2015. - Vol. 23, N 13. - P. 3147-3152.
72. Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl (T315I) mutant / X. Lu [et al.] // Bioorg. Med. Chem. Lett. - 2015. - Vol. 25, N 17. - P. 3458-3463.
73. Discovery of novel Bcr-Abl inhibitors with diacylatedpiperazine as the flexible linker /X. Pan // Org. Biomol. Chem. -2015. - Vol. 13, N 25. - P. 7050-7066.
74. Synthesis of N-Aryl benzamidescontaining pharmacophoric tyrosine kinase inhibitorfragments. E. V. Koroleva [et al.] // Rus. J. Org. Chem. - 2015. - Vol. 51, N 1. - P. 101-109.
75. Bcr-Abl tyrosine kinase inhibitors: a patent review / A. Desogus [et al.] // Expert Opin. Ther. Pat. - 2015. - Vol. 25, N 4. - P. 397-412.